Bullish Moving Averages
8
Bearish Moving Averages
8
Back Stocks profile
Stock analysis tool for investors
Performance
Today’s low
493.00Today’s High
512.0052W low
308.7052W High
590.00Open Price
504.50Prev. Close
538.9000Volume
10542.00Value
5343739.80Fundamentals
Market Cap
526.00
Price to Earnings
22.20
Price to Book Value
2.40
Dividend Yield
0.00
PE to Growth
1.10
Op Revenue TTM
307.17
Net Profit TTM
23.71
Cash From Operating Activity
42.98
Return on Equity %
10.61
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
05 Jul, 2024
62.2
Week
76.2
Month
71.9
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
503.97
PIVOT
First Resistance
514.93
Second Resistance
522.97
Third Resistance
533.93
First Support
495.93
Second Support
484.97
Third Support
476.93
Relative Strength Index
45.62
Money Flow Index
40.12
MACD
-6.47
MACD Signal
-2.65
Average True Range
22.89
Average Directional Index
20.4
Rate of Change (21)
-5.33
Rate of Change (125)
28.23
Commodity Channel Index
-78
Williams %R
-76.2
BETA
1 Month
1.4
3 Month
0.61
1 Year
0.48
3 Year
0.26
PRICE CHANGE ANALYSIS
↑ 3.34%
1 Week
Low
High
489.9
513
↓ -5.94%
1 Month
Low
High
481
590
↑ 5.92%
3 Months
Low
High
441
590
↑ 26.24%
6 Months
Low
High
393.15
590
↑ 59.25%
1 Year
Low
High
308.7
590
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 92.56 | 78.71 | 69.88 | 67.85 | 70.26 | 56.36 | 56.72 | 70.60 | 65.64 | 89.03 | 183.83 | |
| Operating Expenses Qtr | 71.12 | 61.39 | 54.38 | 53.64 | 57.28 | 40.84 | 40.39 | 52.20 | 47.81 | 63.65 | 100.29 | |
| Operating Profit Qtr | 20.86 | 16.70 | 15.27 | 13.81 | 11.52 | 15.17 | 15.57 | 18.02 | 16.23 | 24.54 | 83.42 | |
| EBIDT Qtr Cr | 14.34 | 17.32 | 15.50 | 14.20 | -3.55 | 15.52 | 16.33 | 18.40 | 17.83 | 25.38 | 83.54 | |
| Depreciation Qtr | 5.04 | 4.81 | 4.88 | 4.78 | 4.42 | 3.54 | 3.83 | 3.13 | 2.75 | 3.19 | 2.65 | |
| Net Profit Qtr | 4.50 | 7.70 | 6.26 | 5.45 | -7.36 | 7.23 | 9.05 | 10.55 | 10.15 | 15.89 | 59.66 | |
| Basic EPS Qtr | 4.33 | 7.42 | 6.03 | 5.17 | -7.15 | 6.92 | 8.52 | 10.05 | 9.78 | 15.25 | 57.40 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 309.00 | 253.94 | 459.64 | 263.09 | 142.60 | |
| Operating Expenses Annual Cr | 240.54 | 190.71 | 284.41 | 232.24 | 124.57 | |
| Operating Profit Annual | 66.63 | 60.29 | 171.72 | 29.26 | 14.11 | |
| Operating Profit Margin Annual % | 21.56 | 23.74 | 37.36 | 11.12 | 9.90 | |
| Total Expenses Annual Cr | 270.44 | 211.65 | 297.97 | 241.29 | 131.46 | |
| EBIDT Annual Cr | 68.46 | 63.23 | 175.24 | 30.85 | 18.03 | |
| EBIDT Annual margin % | 22.16 | 24.90 | 38.12 | 11.73 | 12.65 | |
| Depreciation | 19.51 | 14.92 | 10.64 | 6.44 | 4.39 | |
| PAT Before ExtraOrdinary Items Annual Cr | 23.98 | 19.47 | 120.05 | 15.41 | 8.43 | |
| Net Profit Annual | 23.98 | 19.47 | 120.05 | 15.41 | 8.43 | |
| Basic EPS Annual | 23.11 | 18.45 | 115.70 | 14.86 | 8.13 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 225.94 | 202.03 | 182.56 | 62.51 | 47.09 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 19.78 | 28.62 | 30.50 | 28.12 | 19.98 | |
| Total Current Liabilities Annual Cr | 151.85 | 125.94 | 129.62 | 78.15 | 67.61 | |
| Total Capital Plus Liabilities Annual Cr | 397.57 | 356.58 | 342.68 | 168.78 | 134.68 | |
| Fixed Assets Annual | 138.18 | 133.87 | 102.92 | 58.41 | 41.63 | |
| Total Non Current Assets Annual | 154.19 | 149.06 | 115.36 | 62.90 | 46.15 | |
| Total Current Assets Annual | 243.38 | 207.52 | 227.32 | 105.88 | 88.53 | |
| Total Assets Annual | 397.57 | 356.58 | 342.68 | 168.78 | 134.68 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 0.51 | 0.05 | 0.59 | 1.27 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 43.35 | 42.19 | 63.06 | 26.36 | 5.63 | |
| Cash from Investing Activity Annual | -26.40 | -48.44 | -62.98 | -23.20 | -17.13 | |
| Cash from Financing Annual Activity | -17.40 | 0.99 | 5.66 | 0.83 | 12.36 | |
| Net Cash Flow Annual | - | -5.26 | 5.74 | 3.99 | 0.87 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 217.75 | 193.93 | 175.17 | 59.47 | 44.62 | |
| ROE Annual % | 10.61 | 9.67 | 66.04 | 24.97 | 18.21 | |
| ROCE Annual % | 19.92 | 20.94 | 77.25 | 26.93 | 20.33 | |
| Total Debt to Total Equity Annual | 0.43 | 0.45 | 0.24 | 0.56 | 0.68 | |
| EBDIT Annual Margin % | 22.28 | 25.19 | 38.41 | 11.79 | 13.00 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 92.56 | 78.71 | 69.88 | 67.85 | 70.26 | 56.55 | 56.93 | 70.60 | 65.65 | 89.03 | 183.86 | |
| Operating Expenses Qtr | 71.35 | 61.41 | 54.42 | 53.68 | 57.32 | 41.10 | 40.25 | 52.21 | 47.83 | 63.66 | 100.34 | |
| Operating Profit Qtr | 20.62 | 16.69 | 15.23 | 13.77 | 11.48 | 15.10 | 15.55 | 18.00 | 16.22 | 24.53 | 83.40 | |
| EBIDT Qtr Cr | 14.11 | 17.30 | 15.46 | 14.17 | -3.59 | 15.45 | 16.68 | 18.38 | 17.82 | 25.37 | 83.51 | |
| Depreciation Qtr | 5.07 | 4.82 | 4.88 | 4.79 | 4.43 | 3.55 | 3.84 | 3.14 | 2.76 | 3.20 | 2.66 | |
| Net Profit Qtr | 4.36 | 7.69 | 6.24 | 5.42 | -7.38 | 7.14 | 9.42 | 10.54 | 10.50 | -10.50 | 59.60 | |
| Basic EPS Qtr | 4.08 | 7.39 | 5.99 | 5.10 | -7.23 | 6.82 | 8.82 | 9.99 | 9.97 | 14.95 | 57.33 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 309.00 | 253.97 | 459.70 | 263.60 | 142.96 | |
| Operating Expenses Annual Cr | 240.86 | 190.89 | 284.52 | 233.17 | 125.11 | |
| Operating Profit Annual | 66.31 | 60.14 | 171.66 | 28.85 | 14.19 | |
| Operating Profit Margin Annual % | 21.46 | 23.68 | 37.34 | 10.94 | 9.93 | |
| Total Expenses Annual Cr | 270.80 | 211.87 | 298.13 | 242.33 | 132.04 | |
| EBIDT Annual Cr | 68.14 | 63.08 | 175.17 | 30.44 | 17.85 | |
| EBIDT Annual margin % | 22.05 | 24.84 | 38.11 | 11.55 | 12.49 | |
| Depreciation | 19.56 | 14.96 | 10.69 | 6.49 | 4.43 | |
| PAT Before ExtraOrdinary Items Annual Cr | 23.62 | 19.28 | 119.94 | 14.89 | 8.21 | |
| Net Profit Annual | 23.80 | 19.37 | 119.99 | 15.15 | 8.32 | |
| Basic EPS Annual | 22.76 | 18.16 | 115.64 | 14.60 | 8.02 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 224.21 | 200.52 | 181.14 | 61.15 | 46.01 | |
| Minority Interest Liability Annual Cr | -1.63 | -1.45 | -1.35 | -1.30 | -1.04 | |
| Total Non Current Liabilities Annual Cr | 19.78 | 28.62 | 30.50 | 28.12 | 19.98 | |
| Total Current Liabilities Annual Cr | 151.85 | 125.95 | 130.31 | 78.29 | 67.75 | |
| Total Capital Plus Liabilities Annual Cr | 394.21 | 353.63 | 340.59 | 166.26 | 132.69 | |
| Fixed Assets Annual | 139.05 | 134.79 | 103.88 | 59.42 | 42.69 | |
| Total Non Current Assets Annual | 151.52 | 146.43 | 112.77 | 60.36 | 43.66 | |
| Total Current Assets Annual | 242.69 | 207.20 | 227.82 | 105.90 | 89.03 | |
| Total Assets Annual | 394.21 | 353.63 | 340.59 | 166.26 | 132.69 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 0.51 | 0.05 | 0.59 | 1.27 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 42.98 | 41.38 | 64.46 | 26.71 | 6.16 | |
| Cash from Investing Activity Annual | -26.40 | -48.44 | -62.98 | -23.20 | -17.80 | |
| Cash from Financing Annual Activity | -17.40 | 0.99 | 5.66 | 0.77 | 11.77 | |
| Net Cash Flow Annual | - | -6.07 | 7.14 | 4.27 | 0.14 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 214.51 | 191.08 | 172.50 | 56.91 | 42.56 | |
| ROE Annual % | 10.61 | 9.69 | 66.53 | 25.09 | 18.39 | |
| ROCE Annual % | 20.04 | 21.13 | 78.21 | 27.21 | 20.65 | |
| Total Debt to Total Equity Annual | 0.44 | 0.45 | 0.24 | 0.58 | 0.69 | |
| EBDIT Annual Margin % | 22.18 | 25.12 | 38.39 | 11.61 | 12.81 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| DHEERAJ KUMAR LOHIA | 1.92 | 75271992 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| RAMESH ARORA | 26.01 | 75271976 | 0 | 0 |
| AJAY ARORA | 13.59 | 75271977 | 0 | 0 |
| ADITYA ARORA | 11.95 | 75271979 | 0 | 0 |
| ANJU ARORA | 1.31 | 75271980 | 0 | 0 |
| GEETA ARORA | 1.07 | 75271981 | 0 | 0 |
| JUGAL KISHORE HUF | 0.89 | 75271982 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|
| Name | Holding Percent | Holding Id |
|---|---|---|
| DEEPAK BANSAL | 10.63 | 75271991 |
| DHEERAJ KUMAR LOHIA | 1.92 | 75271992 |
| KADAYAM RAMNATHAN BHARAT | 1.66 | 75271993 |
| ONKAR SINGH | 1.02 | 75271994 |
| HUF | 1.79 | 75271986 |
| MANOHAR DEVABHAKTUNI | 4.98 | 75271996 |
| JANI BHASHA SHAIK | 1.45 | 75271997 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Jan 05, 2017 | 0.6 | INTERIM | Jan 06, 2017 | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 23, 2024 | Audited Results | - |
| Feb 06, 2024 | Quarterly Results | - |
| Nov 04, 2023 | Quarterly Results | - |
| Aug 10, 2023 | Quarterly Results | - |
| May 27, 2023 | Audited Results | - |
| Feb 14, 2023 | Quarterly Results | - |
| Nov 14, 2022 | Quarterly Results | - |
| Aug 13, 2022 | Quarterly Results | - |
| May 28, 2022 | Audited & Half Yearly Results | - |
| Nov 10, 2021 | Others | Inter alia, to consider and approve the Migration of the Company from BSE SME Platform to Main Board of BSE Limited subject to approval of shareholders |
| Oct 22, 2021 | Half Yearly Results | - |
| Jun 30, 2021 | Audited & Half Yearly Results | - |
| Nov 13, 2020 | Half Yearly Results | - |
| Jul 13, 2020 | Audited Results | (Revised) |
| Jun 30, 2020 | Audited Results | - |
| Nov 14, 2019 | Half Yearly Results | - |
| May 30, 2019 | Audited Results | - |
| Nov 14, 2018 | Quarterly Results | - |
| May 30, 2018 | Audited Results | - |
| Nov 14, 2017 | Quarterly Results | - |
| Sep 05, 2017 | Bonus issue & Others | To fix and approve the time, date & venue of the 34th Annual General Meeting of the Company. |
| May 30, 2017 | Audited Results | - |
| Mar 20, 2017 | Others | Appointed Mr. JANIBHASHA SHAIK, having Din: 06738842 as an Additional Independent Director of the Company. |
| Dec 22, 2016 | Interim Dividend | - |
| Nov 14, 2016 | Quarterly Results | - |
| Sep 05, 2016 | Audited Results | The Draft Standalone Financial Statements of the Company for the Financial Year ended March 31, 2016. |
| Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
| Oct 11, 2017 | 1:1 | 2017-10-12 |
28 Jun 2024
Kwality Pharmaceuticals Ltd - 539997 - Closure of Trading Window
Closure of Trading Window w.e.f. July 01, 2024
30 May 2024
Kwality Pharmaceuticals Ltd - 539997 - Compliances-Reg.24(A)-Annual Secretarial Compliance
ANNUAL SECRETARIAL COMPLIANCE REPORT FOR 31-03-2024 ATTACHED HEREWITH
27 May 2024
Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Newspaper Publication
NEWSPAPER ADVTS OF FINANCIAL RESULTS ATTACHED HEREWITH
27 May 2024
Kwality Pharmaceuticals Ltd - 539997 - Investor Presentation Of The Results Of The Company For The Financial Year Ended 31St March, 2024
Investor Presentation of FY 24 RESULTS ATTACHED
27 May 2024
Kwality Pharmaceuticals Ltd - 539997 - Investor Presentation Of The Results Of The Company For The Financial Year Ended 31St March, 2024
INVESTOR PRESENTATION OF FY24 RESULTS ATTACHED HEREWITH
23 May 2024
Kwality Pharmaceuticals Ltd - 539997 - Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended 31St March, 2024
We wish to inform you that at the Board Meeting held today i.e. on Thursday, May 23, 2024, the Board of Directors of the Company have inter alia Considered and approved the Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year Ended 31st March, 2024. we are enclosing herewith: a. Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year Ended 31st March, 2024. b. Statement of Assets and Liabilities as at March 31, 2024 and Statement of Cash Flows for the Financial Year Ended 31st March, 2024. c. Declaration pursuant to Regulation 33(3) (d) of the SEBI (LODR) Regulations, 2015, regarding unmodified opinion of the Statutory Auditors on the Annual Financial Results for the Financial Year ended on 31st March, 2024. d. Auditors reports on the Audited Financial Results on Standalone and Consolidated basis.
23 May 2024
Kwality Pharmaceuticals Ltd - 539997 - FINANCIAL RESULTS FOR THE QTR AND YEAR ENDED 31ST MARCH 2024
AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31-03-2024 ALONGWITH OTHER NECESSARY ANNEXURES ARE ATTACHED HEREWITH
08 May 2024
Kwality Pharmaceuticals Ltd - 539997 - Board Meeting Intimation for Considering The Standalone & Consolidated Audited Financial Results For The 4Th Quarter And Financial Year Ended On 31St March, 2024
Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2024 ,inter alia, to consider and approve the Standalone & Consolidated audited financial results for the fourth quarter and financial year ended on 31st March, 2024.Further, as per our earlier communication vide our letter dated 30th March, 2024 and in accordance with the Company's Code of Conduct for Prohibition of Insider Trading framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the Trading window for dealing in Securities of the Company for all the Board of Directors, Designated Persons and their immediate relatives will remain closed till 48 hours after the financial results of the Company are made public on May 23, 2024.This is for your information and record.
30 Apr 2024
Kwality Pharmaceuticals Ltd - 539997 - Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) For The Year Ended On 31St March, 2024
Certificate under regulation 40(9) is attached
29 Apr 2024
Kwality Pharmaceuticals Ltd - 539997 - KWALITY PHARMA RECEIVED INVIMA APPROVAL FOR ITS ONCOLOGY (UNIT-III) VIAL LINE AND TABLET LINE
KWALITY PHARMACEUTICAL MANUFACTURING FACILITY ONCOLOGY(UNIT III) AT HIMCHAL PRADESH HAS RECEIVED INVIMA APPROVAL FOR ITS VIAL LINE AND TABLET LINE.
